MONTE ROSA THERAPEUTICS INC (GLUE) Forecast, Price Target & Analyst Ratings

NASDAQ:GLUE • US61225M1027

Current stock price

18.23 USD
+0.73 (+4.17%)
At close:
18.23 USD
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MONTE ROSA THERAPEUTICS INC (GLUE).

Forecast Snapshot

Consensus Price Target

Price Target
$30.60
+ 67.86% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
-$0.42
Revenue Estimate
8.65M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
85.33%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$30.60
Upside
+ 67.86%
From current price of $18.23 to mean target of $30.60, Based on 15 analyst forecasts
Low
$17.17
Median
$30.60
High
$38.85

Price Target Revisions

1 Month
2.44%
3 Months
40.47%

Price Target Summary

15 Wall Street analysts provided a forecast for the next 12 months for GLUE. The average price target is 30.6 USD. This implies a price increase of 67.86% is expected in the next year compared to the current price of 18.23.
The average price target has been revised upward by 40.47% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

GLUE Current Analyst RatingGLUE Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8

Analyst Ratings History

GLUE Historical Analyst RatingsGLUE Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10

Analyst Ratings Consensus

ChartMill Buy Consensus
85.33%
GLUE was analyzed by 15 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about GLUE.
In the previous month the buy percentage consensus was at a similar level.
GLUE was analyzed by 15 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-18GuggenheimMaintains Buy -> Buy
2026-03-18Wells FargoMaintains Overweight -> Overweight
2026-01-14Piper SandlerReiterate Overweight -> Overweight
2026-01-08GuggenheimMaintains Buy -> Buy
2026-01-08Wells FargoMaintains Overweight -> Overweight
2025-12-16Wells FargoUpgrade Equal-Weight -> Overweight
2025-11-07Wells FargoMaintains Equal-Weight -> Equal-Weight
2025-03-21WedbushMaintains Outperform -> Outperform
2025-03-21Wells FargoMaintains Equal-Weight -> Equal-Weight
2025-03-12LifeSci CapitalInitiate Outperform
2024-12-19Wells FargoDowngrade Overweight -> Equal-Weight
2024-09-12WedbushReiterate Outperform -> Outperform
2024-08-12Wells FargoMaintains Overweight -> Overweight
2024-06-28Piper SandlerReiterate Overweight -> Overweight
2024-05-22WedbushReiterate Outperform -> Outperform
2024-02-15WedbushInitiate Outperform
2023-10-19JP MorganMaintains Overweight -> Overweight
2023-08-11Credit SuisseReiterate Neutral -> Neutral
2023-05-12Credit SuisseReiterate Neutral -> Neutral
2023-03-17Credit SuisseMaintains Neutral
2023-01-03Wells FargoUpgrade Equal-Weight -> Overweight
2022-10-13UBSInitiate Buy
2022-08-15JefferiesInitiate Buy
2022-05-12Piper SandlerMaintains Overweight
2022-04-28Credit SuisseInitiate Neutral

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
-$0.42
Revenue Estimate
8.65M
Revenue Q2Q
-89.82%
EPS Q2Q
-175.29%
Number of Analysts
8

Next Earnings Revisions

Revenue (1 Month)
182.68%
Revenue (3 Months)
182.68%
EPS (1 Month)
13.09%
EPS (3 Months)
10.46%

Next Earnings Summary

GLUE is expected to report earnings on 5/7/2026. The consensus EPS estimate for the next earnings is -0.42 USD and the consensus revenue estimate is 8.65M USD.
The next earnings revenue estimate has been revised upward by 182.68% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
GLUE revenue by date.GLUE revenue by date.
75.622M123.672M
63.54%		57.902M
-53.18%		62.686M
8.26%		23.888M
-61.89%		72.444M
203.27%		204.11M
181.75%		692.43M
239.24%		1.475B
113.02%		2.217B
50.31%
EBITDA
YoY % growth
GLUE ebitda by date.GLUE ebitda by date.
-137.089M
-26.20%		-72.991M
46.76%		-45.852M
37.18%		-23.46M
48.84%		48.96M
308.70%		N/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
GLUE ebit by date.GLUE ebit by date.
-143.311M
-27.52%		-81.112M
43.40%		-54.208M
33.17%		-142.942M
-163.69%		-170.834M
-19.51%		-233.146M
-36.48%		-226.894M
2.68%		-145.88M
35.71%		314.56M
315.63%		1.043B
231.57%		1.74B
66.83%
Operating Margin
GLUE operating margin by date.GLUE operating margin by date.
N/A-107.26%-43.83%-246.87%-272.52%-975.99%-313.20%-71.47%45.43%70.71%78.48%
EPS
YoY % growth
GLUE eps by date.GLUE eps by date.
-2.64
-15.28%		-1.02
61.36%		-0.48
52.94%		-1.68
-250.20%		-1.77
-5.04%		-2.03
-14.78%		-2.03
-0.06%		-1.10
45.67%		3.77
442.59%		11.05
192.84%		17.08
54.55%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.42
-175.29%		-0.45
-198.06%		-0.47
-43.93%		-0.49
12.06%		-0.46
-8.87%		-0.50
-11.79%		-0.51
-7.37%		-0.55
-11.84%
Revenue
Q2Q % growth		8.65M
-89.82%		7.222M
-68.86%		7.222M
-43.44%		7.222M
159.69%		10.2M
17.92%		10.2M
41.24%		10.2M
41.24%		10.2M
41.24%
EBITDA
Q2Q % growth		-15.3M
-133.20%		-5.1M
55.19%		-6.12M
77.08%		3.06M
107.40%		N/AN/AN/AN/A
EBIT
Q2Q % growth		-45.818M
-204.05%		-49.388M
-217.53%		-52.142M
-58.13%		-54.509M
-9.64%		-51M
-11.31%		-54.57M
-10.49%		-55.08M
-5.63%		-58.65M
-7.60%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

GLUE Yearly Revenue VS EstimatesGLUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
GLUE Yearly EPS VS EstimatesGLUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10 15

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-61.62%
EPS Next 5 Year
-18.07%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
-44.42%
Revenue Next 5 Year
7.96%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

MONTE ROSA THERAPEUTICS INC / GLUE Forecast FAQ

Can you provide the average price target for MONTE ROSA THERAPEUTICS INC stock?

15 analysts have analysed GLUE and the average price target is 30.6 USD. This implies a price increase of 67.86% is expected in the next year compared to the current price of 18.23.

When does MONTE ROSA THERAPEUTICS INC (GLUE) report earnings?

MONTE ROSA THERAPEUTICS INC (GLUE) will report earnings on 2026-05-07.

What are the consensus estimates for MONTE ROSA THERAPEUTICS INC (GLUE) next earnings?

The consensus EPS estimate for the next earnings of MONTE ROSA THERAPEUTICS INC (GLUE) is -0.42 USD and the consensus revenue estimate is 8.65M USD.

What is the number of analysts for GLUE stock?

The number of analysts covering MONTE ROSA THERAPEUTICS INC (GLUE) is 15.